Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03089554 · ClinicalTrials.gov registry record · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
A Phase 2 study of Cancer, sponsored by Rachel Miller.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 1
- Study location
NCT03089554: Recruiting Phase 2 study of Cancer, sponsored by Rachel Miller.
NCT03089554 is a Phase 2 study of Cancer that is actively recruiting participants, run by Rachel Miller. The registered enrollment target is 93 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03089554, a Phase 2 study of Cancer, is actively recruiting participants, sponsored by Rachel Miller.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based on genomic analysis results and recommendation by the Markey Cancer Center Molecular Tumor Board (MCC MTB).
Conditions Studied
Interventions
- DRUG Therapeutic Intervention
Study Locations (1)
Kentucky
- Markey Cancer Center, University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2017-04-11 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03089554
The ClinicalTrials.gov registry entry for NCT03089554 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Rachel Miller, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Therapeutic Intervention is the first listed.
NCT03089554 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT03089554 about?
NCT03089554 is a clinical study titled "Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies". This is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based on genomic analysis results and recommendation by the Markey Cancer Ce...
What is the current status of trial NCT03089554?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2017-04-11. Estimated completion is 2026-04.
What conditions does trial NCT03089554 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT03089554?
The interventions under investigation include: Therapeutic Intervention (DRUG).
Who is sponsoring clinical trial NCT03089554?
This trial is sponsored by Rachel Miller, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03089554 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.